ABIONYX Pharma Announces Unanimous Approval of All Resolutions Put to the Vote at Its Combined General Meeting
29 Junho 2023 - 1:00PM
Business Wire
ABIONYX Pharma, (FR0012616852 - ABNX - PEA PME eligible),
a new generation biotech company dedicated to the discovery and
development of innovative therapies based, announces that all
resolutions presented at its Combined General Meeting were
unanimously approved.
Among the resolutions adopted were the renewal of the mandates
of Laura A. Coruzzi, Karen Noel and Cyrille Tupin, Chief Executive
Officer of ABIONYX Pharma, for a 3-year term. Shareholders also
approved the renewal of the share buyback program and of the
liquidity contract.
ABIONYX Pharma would like to thank all shareholders present,
represented or having voted by post for their commitment and
support at this General Meeting.
The minutes of the General Meeting and the results of the votes
by resolution are available on the Company's website in the
Shareholder Meeting section.
About ABIONYX Pharma
ABIONYX Pharma is a new generation biotech company that aims to
contribute to health through innovative therapies in indications
where there is no effective or existing treatment, even the rarest
ones. Thanks to its partners in research, medicine,
biopharmaceuticals and shareholding, the company innovates on a
daily basis to propose drugs for the treatment of renal and
ophthalmological diseases, or new HDL vectors used for targeted
drug delivery.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230629699834/en/
NewCap Investor relations Louis-Victor Delouvrier Nicolas
Fossiez abionyx@newcap.eu +33 (0)1 44 71 98 53
NewCap Media relations Arthur Rouillé abionyx@newcap.eu
+33 (0)1 44 71 94 98
Abionyx Pharma (EU:ABNX)
Gráfico Histórico do Ativo
De Abr 2024 até Mai 2024
Abionyx Pharma (EU:ABNX)
Gráfico Histórico do Ativo
De Mai 2023 até Mai 2024